Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
Group Therapy01:26

Group Therapy

472
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
472

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated Tumors.

The New England journal of medicine·2026
Same author

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Cancer research communications·2026
Same author

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.

Clinical and translational science·2026

Related Experiment Video

Updated: Feb 15, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K

Improving combination cancer therapy: the CombiPlex® development platform.

Anthony W Tolcher1, Lawrence D Mayer2

  • 1South Texas Accelerated Research Therapeutics, Suite 4022, 4383 Medical Drive, San Antonio, TX 78230, USA.

Future Oncology (London, England)
|January 25, 2018
PubMed
Summary

Current cancer therapies often fail to deliver synergistic drug ratios due to pharmacokinetic differences and toxicity. The CombiPlex platform enables precise delivery of combination treatments, as demonstrated by CPX-351, improving therapeutic outcomes.

Keywords:
CPX-351combination chemotherapyliposomes

More Related Videos

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

14.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Related Experiment Videos

Last Updated: Feb 15, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

14.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Combination cancer therapy often aims for maximal drug doses, but achieving synergistic ratios in tumors is challenging.
  • Individual drug pharmacokinetics and dose-limiting toxicities can compromise the efficacy of conventional combination regimens.
  • Novel delivery systems are needed to overcome these limitations and ensure drugs reach tumor cells at synergistic ratios.

Purpose of the Study:

  • To introduce the CombiPlex platform for optimizing combination drug delivery.
  • To demonstrate the ability of CombiPlex to determine and maintain synergistic drug ratios in vivo.
  • To present CPX-351 as a clinical example of this drug delivery technology.

Main Methods:

  • In vitro determination of synergistic drug ratios.
  • Identification of suitable nanoscale carriers for drug encapsulation.
  • In vivo evaluation of drug delivery and ratio maintenance using the CombiPlex platform.
  • Development of CPX-351, a liposomal formulation of cytarabine and daunorubicin.

Main Results:

  • The CombiPlex platform can identify synergistic drug combinations and suitable delivery vehicles.
  • Nanoscale carriers can maintain specific drug ratios during in vivo circulation.
  • CPX-351, utilizing the CombiPlex technology, represents a successful clinical application.

Conclusions:

  • The CombiPlex platform offers a novel approach to enhance combination cancer therapy efficacy.
  • Precise control over drug ratios and delivery can overcome pharmacokinetic and toxicity challenges.
  • CPX-351 validates the potential of CombiPlex technology in clinical settings.